Home
GATEWAY to Global Voices
METAGATEWAY An Expert Dialogue Series
Login
Role of GLP-1RA beyond the metabolic disease management
Issue 6 | Vol. 1 | May 2026
Faculty
Prof. Donna H. Ryan, MD
Professor Emerita, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
Summary
Dr Donna Ryan highlights the evolution of GLP-1 receptor agonists from metabolic agents to true disease-modifying therapies…
Renal Protective Effects of GLP 1-RA in Patients with Type 2 Diabetes and CKD- New updates
Issue 5 | Vol. 1 | Apr. 2026
Faculty
Richard Pratley, M.D.
Samuel Crockett Chair in Diabetes Research Medical Director, AdventHealth Diabetes Institute Senior Scientist and Diabetes Program Head, AdventHealth Translational Research Institute Adjunct Professor, Johns Hopkins School of Medicine Orlando, Florida
Summary
Dr. Richard E. Pratley highlights that chronic kidney disease is a common and deadly complication of type 2…
Insights from the SELECT Trial: Impact on Cardiovascular Outcomes in Obesity
Issue 4 I Vol. 1 I Jan. 2026
Faculty
Marc-Andre Cornier, MD
Professor of Medicine
James A. Keating Endowed Chair in Diabetes
Director, Division of Endocrinology, Diabetes & Metabolic Diseases
Medical University of South Carolina
Summary
Dr. Marc-Andre Cornier reviewed the pivotal SELECT trial, which evaluated semaglutide 2.4 mg in overweight or obese…
Obesity and Cardiovascular Risk: The Rationale for GLP Therapy with a Focus on Semaglutide
Issue 3 I Vol. 1 I Nov. 2025
Faculty
Marc Cornier, M.D
Professor of Medicine
James A. Keating Endowed Chair in Diabetes
Director, Division of Endocrinology, Diabetes & Metabolic Diseases
Medical University of South Carolina
Summary
The presentation highlights obesity as a major independent risk factor for cardiovascular disease and explains the mechanisms…
Semaglutide in Type 2 Diabetes - Efficacy in Glycemic Control Compared to Other Agents
Issue 2 I Vol. 1 I Sep. 2025
Faculty
Richard Pratley, M.D.
Samuel Crockett Chair in Diabetes Research Medical Director, AdventHealth Diabetes Institute Senior Scientist and Diabetes Program Head, AdventHealth Translational Research Institute Adjunct Professor, Johns Hopkins School of Medicine, Orlando, Florida
Summary
Dr. Richard Pratley reviewed the evidence for semaglutide in type 2 diabetes management, focusing on the SUSTAIN…
Mechanism of Action of GLP-1 Receptor Agonists in Obesity Treatment
Issue 1 I Vol. 1 I Aug. 2025
Faculty
Prof. Donna H. Ryan, MD
Professor Emerita, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
Summary
This presentation by Dr. Donna Ryan highlights the evolving understanding and therapeutic potential of GLP-1 receptor agonists. Initially used for…